ProfileGDS5678 / 1417101_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 56% 60% 59% 53% 56% 55% 56% 59% 51% 56% 53% 56% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8450464
GSM967853U87-EV human glioblastoma xenograft - Control 23.4269956
GSM967854U87-EV human glioblastoma xenograft - Control 33.5828660
GSM967855U87-EV human glioblastoma xenograft - Control 43.5159259
GSM967856U87-EV human glioblastoma xenograft - Control 53.2512753
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5150156
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4758355
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4091556
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5182159
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2094951
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4106656
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2752753
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4122156
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0961947